Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing...
-
Call scheduled for Wednesday, November 14 at 4:30pm Eastern Time NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC: AITB), a clinical-stage medical device and...
-
Seasoned expert with three decades of financial planning and management experience to join AIT Team GARDEN CITY, N.Y., and REHOVOT, Israel, Oct. 26, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc....
-
GARDEN CITY, N.Y. and REHOVOT, Israel, Oct. 18, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing...
-
GARDEN CITY, N.Y. and REHOVOT, Israel, Oct. 16, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing...
-
NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the...
-
GARDEN CITY, N.Y. and REHOVOT, Israel, Sept. 19, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing...
-
GARDEN CITY, N.Y. and REHOVOT, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB:AITB) (“AIT Therapeutics or the “Company”), a clinical-stage medical device and...
-
Highlights at European Respiratory Society (ERS) to include updated data from company’s NO-BRO Pilot study of high-dose inhaled nitric oxide (NO) in infants hospitalized with acute bronchiolitis ...
-
Started commercial development of ventilator compatible NO generator and delivery system -- FDA 510(k) submission expected in the first quarter of calendar 2019 Human and in-vitro Nitric Oxide (NO)...